Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 10/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12598149 | 1.00 | ELANE (0.48) | ELANECYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL8168154 | 0.90 | CMA1 (0.51) | ELANECMA1CTSLCTSBCTSK | |
| SCHEMBL8352620 | 0.90 | CMA1 (0.51) | ELANECMA1CTSLCTSBCTSK | |
| SCHEMBL7316962 | 0.90 | CMA1 (0.51) | ELANECMA1CTSLCTSBCTSK | |
| SCHEMBL12599485 | 0.89 | CYP3A4 (0.49) | ELANECYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL13258959 | 0.86 | CMA1 (0.51) | ELANECMA1CTSLCTSBCTSK | |
| SCHEMBL12566960 | 0.86 | DPP4 (0.51) | ELANECYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL15692923 | 0.85 | FKBP1A (0.46) | ELANECYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL7362827 | 0.84 | CMA1 (0.45) | ELANECMA1 | |
| SCHEMBL8168155 | 0.84 | CMA1 (0.61) | ELANECMA1CTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814699-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-06-09 | — | — | US | disclosed |
| EP-3006441-A1 | NS5A INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150374668-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2015-12-31 | — | — | US | disclosed |
| US-9150587-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140371455-A1 | Chemical compounds | JANSSEN PHARMACEUTICALS INC (US) | 2014-12-18 | — | — | US | disclosed |
| US-8853416-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130274304-A1 | Chemical Compounds | Janssen Pharmaceuticals, Inc. | 2013-10-17 | — | — | US | disclosed |
| US-8492554-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130072690-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-8344155-B2 | Chemical compounds | GLAXOSMITH KLINE LLC (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2011091446-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20110152237-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2011-06-23 | — | — | US | disclosed |
| US-6054593-A | Proline derivatives | ZENECA LIMITED (GB) | 2000-04-25 | — | — | US | disclosed |
| US-6048889-A | Proline derivatives | ZENECA LIMITED (GB) | 2000-04-11 | — | — | US | disclosed |
| US-5808097-A | OXIDATION OF THE CORRESPONDING HYDROXY COMPOUND | ZENECA LIMITED (GB) | 1998-09-15 | — | — | US | disclosed |
| EP-0808327-A1 | PROLINE DERIVATIVES USEFUL AS INHIBITORS OF HUMAN LEUKOCYTE ELASTASE | ZENECA LIMITED (GB) | 1997-11-26 | — | — | EP | disclosed |
| US-5686628-A | Proline derivatives | ZENECA LTD. (GB) | 1997-11-11 | — | — | US | disclosed |
| WO-1996023812-A1 | PROLINE DERIVATIVES USEFUL AS INHIBITORS OF HUMAN LEUKOCYTE ELASTASE | ZENECA LIMITED (GB) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374668-A1 | CHEMICAL COMPOUNDS | SLC10A1, UGT1A3, UGT2B7 | ELANE 181/4885CYP3A4 52/4885CYP2C9 40/4885 |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | SLC10A1, UGT1A3, UGT2B7 | ELANE 181/4885CYP3A4 52/4885CYP2C9 40/4885 |
| US-20140371455-A1 | Chemical compounds | SLC10A1, UGT1A3, UGT2B7 | ELANE 181/4885CYP3A4 52/4885CYP2C9 40/4885 |
| US-20130072690-A1 | Chemical Compounds | SLC10A1, UGT1A3, UGT2B7 | ELANE 181/4885CYP3A4 52/4885CYP2C9 40/4885 |
| US-20130274304-A1 | Chemical Compounds | SLC10A1, UGT1A3, UGT2B7 | ELANE 181/4885CYP3A4 52/4885CYP2C9 40/4885 |
| US-20110152237-A1 | Chemical Compounds | SLC10A1, UGT1A3, UGT2B7 | ELANE 181/4885CYP3A4 52/4885CYP2C9 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.